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Our objective was to look for differences in susceptibility patterns between Norwegian
and imported methicillin-resistant Staphylococcus aureus (MRSA) strains. All MRSA
isolates from the participating hospitals (87 isolates from 81 patients) throughout the
period 1994–98 were examined, to study the clonal distribution of MRSA isolated in
Norway and to identify any epidemic clones among the isolates. We found that imported
isolates were resistant to an average of 5.6 antibiotics, while Norwegian isolates were
resistant to an average of 2.6 antibiotics. MRSA isolates imported to Norway are more
often multiresistant than domestic isolates. MRSA isolates in Norway show a striking
diversity. Epidemic clones are present, but no single clone is predominant.
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The prevalence of methicillin-resistant Staphylococ-
cus aureus (MRSA) has previously been low in
Norway. Only a few local outbreaks have been
reported, all with a limited number of patients
[1–3]. Since 1995, infection with MRSA has been
notified to the Norwegian Notification System
for Infectious Diseases (MSIS). The incidence
increased from 22 in 1995 to 113 in 2001 [4]. Other
countries have estimated prevalences for MRSA as
high as 40–60% [5–12]. The high prevalence in
these countries has been of great concern, because
once MRSA is introduced into a hospital, it may be
difficult to eradicate. The most serious problems
have occurred in countries in which the highly
epidemic multiresistant ‘Iberian’ or ‘Brazilian’
clones have been introduced [8,13–17], or in the
UK, where E-MRSA 15 and 16 are now epidemic
[18]. Other countries have reported high frequen-
cies of non-epidemic strains [7,9,11,12,19]. This
emphasizes the need for rapid typing systems in
order to clarify the epidemiologic situation.
In Norway, about 50% of the MRSA isolates are
imported from various countries. The remainder
are termed ‘Norwegian’ strains, and are presumed
to be of domestic origin, with no apparent
connection with recent travel abroad. Since
there has been an increase in the prevalence of
MRSA infections in Norway, it would be of great
interest to verify that this is due to the introduction
of epidemic clones. The aim of the present study
was therefore to investigate the epidemiology of
the imported strains, and to look for epidemic
clones among the strains of domestic origin.
All Norwegian medical microbiology depart-
ments were approached and invited to contribute
MRSA isolates. Fifteen of 18 clinical microbiologi-
cal laboratories in Norway took part in the study.
These 15 laboratories represent 3.4 million (75.6%)
of a total of 4.5 million inhabitants. In total, 87
isolates from 81 patients, representing 66% of the
notified Norwegian MRSA isolates between 1994
and December 1998, were assembled. Participating
departments were asked to supply information on
foreign travel, particularly hospitalization abroad
and known or suspected epidemiologic associa-
tion with other cases of MRSA infection. Five
isolates were from 1994, 11 from 1995, 13 from
1996, 28 from 1997, and 30 from 1998.
Reference strains of epidemic MRSA clones
were received from CCUG in Gothenburg,
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Sweden (E-MRSA 15 and 16), and from Herminia
de Lencastre (HPV 107, HUSA 304, HSJ 216, HDE
288, and BK 2464).
All MRSA isolates were initially isolated in the
local laboratory and kept frozen at 70 8C until
storage at one laboratory (A/S Telelab, Skien). On
receipt, isolates were subcultured on blood agar
plates and frozen at70 8C in brain–heart infusion
broth with 10% glycerol.
All isolates were confirmed as S. aureus with the
Monostaph agglutination test (Bionor, Skien,
Norway) and a DNase agar test (Mast, Merseyside,
UK). Three of 87 isolates showed discrepant
results between the two tests, and were confirmed
as S. aureus by the tube coagulase test (bioMe`rieux,
Lyon, France).
Antibiotic susceptibility was determined using
the agar diffusion method on DST agar (Mast),
using tablets supplied by Rosco (Taastrup,
Denmark). Interpretation of the zone diameters
as sensitive, intermediate or resistant was done
according to the guidelines of The Norwegian
Working Group on Antibiotics [20]. The following
antibiotics were tested (corresponding resistance
breakpoints are given in mg/L): fusidic acid 1,
clindamycin4, oxacillin4, penicillin G, penase,
erythromycin 4, chloramphenicol 8, vancomy-
cin16, teicoplanin16, netilmicin8, and cipro-
floxacin 8.
Screening for oxacillin resistance was per-
formed on Mueller–Hinton agar (Mast) containing
oxacillin 6 mg/L and NaCl 4% according to
NCCLS guidelines [21]. MICs of oxacillin were
determined using the Etest (AB Biodisk, Solna,
Sweden) on Mueller–Hinton agar (Mast) contain-
ing NaCl 4%. Oxacillin resistance was confirmed
with mecA PCR, performed as described by
Predari et al. [22]. Taq polymerase was obtained
from Promega (Madison WI, USA), and the PCR
program was run on an Omnigene thermal cycler
(Hybaid, Teddington, UK).
Pulsed-field gel electrophoresis (PFGE) was
done according to the Nordic protocol [23]. Gels
were stained with SYBR–gold (Molecular Probes,
Leiden, The Netherlands) according to the manu-
facturer’s instructions, and photographed under
320-nm UV transillumination, using Polaroid 665
film, an SYRB green filter, and a 60-s exposure
time.
Pattern comparisons were done by eye. Initial
gels were scanned for identical patterns, and
representative patterns were included on all
subsequent gels as reference standards. For inter-
pretation of identity, the criteria of Tenover et al.
[24] were used.
Statistical analysis was performed using the
chi-squared and Fisher’s exact test.
Information supplied indicated that 36 of the
isolates were imported. These 36 isolates were
imported from 17 different countries in four con-
tinents; the USA, Spain and the UK contributed
most, with five, four and three isolates each
respectively. The remaining 51 isolates were from
patients with no history of recent travel abroad or
known contact with travelers.
All isolates were resistant to oxacillin and peni-
cillin. None was resistant to vancomycin. In
Table 1, antibiotic resistance among Norwegian
and imported isolates are compared. Resistance
to clindamycin, erythromycin, chloramphenicol,
netilmicin and ciprofloxacin was significantly
more frequent in imported isolates, while resis-
tance to fusidic acid was significantly more fre-
quent in Norwegian isolates (34%) than in
imported isolates (3%). Imported isolates were
resistant to an average of 5.6 antibiotics, while
Norwegian isolates were resistant to an average
of 2.6 antibiotics. All differences were significant
(P < 0.05). MIC values for oxacillin were also
significantly higher in imported isolates than
for the ‘Norwegian’ isolates (MIC 172 versus
89 mg/L, P < 0.001). This suggests that the major-
ity of Norwegian isolates still possess the more
heterogeneous methicillin-resistant phenotype,
which precedes the establishment of stable,
high-level resistance [25].
In total, 58 different PFGE patterns were identi-
fied among the 87 isolates analyzed. Twelve of these
patterns (2a/2b, 5/5, 7a/7b, 11a/11b, 30a/30b
and 34a/34b) were closely related pairs. The dif-
ference between patterns 5 and 5 was subtle, and
the distinction could be made only on gels of
optimum quality. Sixteen patterns (2a, 5, 5, 6,
7a, 7b, 8, 11b, 13, 15, 27, 30a, 34a, 48, 49) contained
two to six isolates. Norwegian isolates were found
in classes 5/5, 8, 11a/11b, 13, 15, 30a/30b, 47, 48,
and 49, while imported isolates were found in
classes 2a/2b, 6, 7a/7b, and 47. The remaining
42 patterns were represented by only one isolate.
A comparison of PFGE results with available
epidemic MRSA strains showed that all seven
epidemic clones were represented among our
imported isolates and among Norwegian isolates
from the same hospital. Spread between different
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Table 1 Characteristics of selected PFGE classes
Class
International
MSRA clone
Number
of isolates
Number
of patients Characteristics
2a/2b ‘Iberian’ HPV 107 3 2 Import isolates. 2a isolates sensitive
only to fusidic acid and vancomycin. 2b
appears to have developed from 2a
(isolates from same patient in 1995 and
1996) with loss of ciprofloxacin and
clindamycin resistance. MIC
oxacillin >256 mg/L
5/5 8 6 Norwegian isolates. 1994–98. MIC
oxacillin 48 mg/L. Three of the
isolates from a cystic fibrosis patient
and his/her mother. Variable
antibiotic resistance patterns even where
isolated from same patient. Pattern 5
isolates are fusidic acid resistant.
Pattern 5 isolates are fusidic acid
sensitive
6 E-MRSA 15
CCUG 42822
3 3 Patients hospitalized in Spain or UK
7a/7b E-MRSA 16
CCUG 43507
4 3 Patients hospitalized in Spain or USA. MIC
oxacillin >256 mg/L. Ciprofloxacin
resistant, erythromycin resistant,
chloramphenicol intermediate
8 3 3 Norwegian isolates. 1994–97. MIC oxacillin
24 mg/L. Chloramphenicol intermediate,
netilmicin intermediate, or sensitive
to all antibiotics except oxacillin and
penicillin G
11a/11b 3 2 All from cystic fibrosis patients in
1995. Same hospital. MIC
oxacillin 48 mg/L, but varying
resistance for other
antibiotics
13 3 3 Norwegian isolates. MIC
oxacillin 8–256 mg/L. Fusidic acid
resistant, netilmicin intermediate, or
netilmicin sensitive. Sensitive to all
other antibiotics. 1997–97
15 2 2 Norwegian isolates. MIC
oxacillin 48 mg/L
27 3 3 Child from Romania and adoptive parents.
MIC oxacillin 12 mg/L, but some
variation in resistance to other
antibiotics
28 ‘Hungarian’ HUSA 304 1 1 Litauen
30a/30b 5 5 30a fusidic acid resistant, MIC
oxacillin 32 mg/L. 30b sensitive
to all antibiotics, MIC oxacillin
128 mg/L. All
strains isolated in Tromsø,
1994–96
34a/34b 2 2 Same hospital. 1997, 1998
44 ‘Pediatric’ HDE 288 1 1 Nicaragua
47 ‘Brazilian’ HSJ 216 3 2 Same hospital. 1998. MIC
oxacillin >256 mg/L. Ciprofloxacin
resistant, erythromycin resistant,
clindamycin intermediate,
netilmicin resistant, gentamicin
resistant. First patient operated on
in Italy
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hospitals was not demonstrated. The characteris-
tics of the 16 PFGE classes containing multiple
isolates and the classes that were identical with
some of the epidemic clones are shown in Table 1.
Examples of PFGE results are shown in Figure 1.
Susceptibility testing showed that the imported
MRSA isolates were multiresistant to a higher
degree than the domestic isolates. This probably
reflects differences in antibiotic prescription prac-
tices between Norway and the countries from
which the MRSA isolates were imported. Heavy
antimicrobial use promotes the selection of anti-
biotic-resistant microorganisms, and differences in
antibiotic susceptibility patterns between different
countries may, at least in part, be explained by
differences in antibiotic prescription practices. The
higher MIC values for oxacillin for the imported
MRSA isolates indicate that these isolates express
the homogeneous resistance phenotype. It seems
likely that Norwegian MRSA isolates are still at an
early stage in their development towards homo-
geneous oxacillin resistance. Domestic isolates
were, however, more frequently resistant to fusi-
dic acid. Fusidic acid is traditionally used for
topical treatment of S. aureus skin infections in
Norway. Mupirocin is not registered in Norway.
Resistance to fusidic acid is now an increasing
problem in Norway [26], and also in Sweden [27].
Our PFGE results demonstrate a striking diver-
sity of MRSA strains in Norway, with a total of 58
different PFGE patterns being found. Fifty-nine
isolates could be assigned to 14 clonal groups with
two to eight members. Of these, four groups (PFGE
classes 5, 8, 13, and 15) represented by 16 isolates
seem to have spread between Norwegian hos-
pitals. The members of the remaining clonal
groups appear either to have been independently
imported from abroad or to have been involved in
small, contained, local outbreaks. We demon-
strated that seven epidemic clones included in
Table 1 continued
Class
International
MSRA clone
Number
of isolates
Number
of patients Characteristics
48 4 4 Same hospital. 1998. MIC
oxacillin >256 mg/L. Ciprofloxacin
resistant, erythromycin resistant,
chloramphenicol intermediate, netilmicin
intermediate, ciprofloxacin resistant.
Two isolates within one family
49 3 3 Same hospital. 1998. Ciprofloxacin
resistant, erythromycin resistant,
chloramphenicol intermediate, netilmicin
intermediate, ciprofloxacin
intermediate, or ciprofloxacin
resistant. MIC oxacillin 4–256 mg/L
50 ‘NY/Tokyo’ BK 2464 1 1 Germany
Figure 1 (A) PFGE results of imported MRSA isolates and
international MRSA clones. Lanes 1, 8 and 13: NCTC 8325.
Lanes 2, 4, 5, 7, 10, 11, 12 and 15 represent our DNA classes
2a, 2b, 7a, 7b, 41, 42 and 44. Lane 3 is HPV 107, lane 6 is E-
MRSA 16, lanes 9 and 12 are HDE 288, and lane 15 is BK
2464. (B) PFGE results that show our heterogeneous DNA
classes 14–29.
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our study were found among isolates imported to
Norway. Some of these isolates were also found
among domestic isolates from the same hospital,
but spread between hospitals could not be demon-
strated. The results of this study in Norway differ
from similar reports from most other countries.
Spain [6], Portugal [10], Hungary [11], Poland [19],
Argentina [15] and the Czech Republic [17] have
all reported widespread dissemination of unique
MRSA clones. There is clear evidence for geo-
graphic spread of MRSA clones between Spain
and Portugal [13,14] and to Italy and Scotland
[16], where both the ‘Iberian’ and ‘Brazilian’ clones
are prevalent; in Brazil,>70% of MRSA isolates are
reported to belong to the same ‘Brazilian’ clone [8].
The MRSA-15 strain has spread from the UK to
Australia, New Zealand, Germany, Sweden, and
Finland [18]. Other countries, e.g. Poland [19] and
Hungary [11], have reported their own epidemic
clones, widely distributed among many hospitals
throughout the country. From New York [28] and
pediatric hospitals in Portugal [29], Poland [19]
and Denmark [30] there have been reports indi-
cating that ‘archaic’ clones persist, in some
instances together with new, highly epidemic
strains. Our findings indicate that Norway is still
in the first stage in the evolutionary process of
emergence of MRSA with a predominantly hetero-
geneous methicillin-resistant phenotype. In con-
trast to the report from Denmark from the early
1960s [30], where MRSA isolates showed a closely
related PFGE profile, the Norwegian isolates have
different PFGE profiles, indicating horizontal
mecA transfer [31]. No strain, either imported or
Norwegian, has yet achieved epidemic spread in
Norway. A similar situation, with low prevalences
of MRSA, is reported for the other Nordic coun-
tries and The Netherlands [32].
An extensive surveillance program has been
implemented for screening healthcare workers
and patients coming from hospitals outside the
Nordic countries and The Netherlands. It is impor-
tant for this program to be continued in order to
prevent MRSA strains being introduced into the
Norwegian hospital environments, particularly
because Norway has arrangements with several
foreign hospitals for the surgical treatment of
certain specified diseases. Similarly, when MRSA
is detected, early screening of patients and staff for
MRSA is an important measure to prevent the
establishment and spread of MRSA within hos-
pitals and other institutions. This also entails
both strict infection control and staff education
programs in all hospitals. It is further desirable
to establish a central reference laboratory for
genetic mapping of typing of all MRSA isolates
in Norway. This would permit identification of
recognized international epidemic clones as soon
as they were introduced, and tracking of new
clones of domestic origin.
A nationwide surveillance system for microbial
resistance (NORM), similar to those in other
Nordic countries (DANMAP in Denmark,
STRAMA in Sweden, and FiRe in Finland) and
involving all Norwegian medical microbiologi-
cal laboratories, was established in 2000. This
continuous surveillance system will include both
notifiable microorganisms and other important
human and animal bacteria, and is a part of a
nationwide plan of action to combat antibiotic
resistance [33].
Norway, the other Nordic countries and The
Netherlands seem, until now, to have escaped
the MRSA problem that besets the majority of
other countries. This is probably due to the rela-
tively low consumption of antibiotics and exten-
sive surveillance programs. Maintaining this low
incidence will require continuation of the mea-
sures that are already in place: early screening
of other patients and staff when MRSA is detected,
screening programs for patients and staff from
abroad, strict hospital infection control programs,
and a restrictive policy for antimicrobial pres-
cription.
The Norwegian MRSA study group includes:
E. Ragnhildstveit, Department of Microbiology,
Østfold Central Hospital, Fredrikstad; F. Mu¨ller,
Department of Microbiology, Bærum Hospital,
Bærum; T. Skarpaas, Department of Microbiology,
Vest-Agder Central Hospital, Kristiansand; O. B.
Nata˚s, Department of Microbiology, Rogaland
Central Hospital, Stavanger; A. Digranes, Depart-
ment of Microbiology and Immunology, Hauke-
land Hospital, Bergen; R. Hjetland, Department of
Microbiology, Sogn and Fjordane Central Hospi-
tal, Førde; E. Vik, Department of Microbiology,
Molde County Hospital, Molde; L. Mortensen,
Department of Microbiology, Nordland Central
Hospital, Bodø; L. Vorland, Department of
Microbiology, University Hospital, Tromsø; R.
Schøyen, Department of Microbiology, Vestfold
Central Hospital, Tønsberg; and S. H. Ringertz,
Department of Microbiology, Aker Hospital,
Oslo.
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